OR WAIT null SECS
Sartorius will invest approximately €270 million (US$305 million) to expand its biopharmaceutical manufacturing activities in South Korea’s biopharm hub.
Sartorius is investing approximately €270 million (US$305 million) through the end of 2024 to expand its activities in South Korea, the company announced on Nov. 25, 2021. Using the investment funds, the company plans to launch cell culture media production in Songdo, Incheon, South Korea’s biopharma hub, in addition to assembling sterile systems for efficient and flexible biopharmaceutical manufacturing, among other operations.
Construction of new facilities at the 25,000-m2 (270,000-ft2) site will include an application center with laboratories as well as several buildings for manufacturing and logistics. Construction is slated to begin in the coming year with production operations scheduled to start by the end of 2024. The expansion will create approximately 750 new jobs. Sartorius’ existing activities for service as well as for marketing and sales will be relocated to the new site.
“The development of the biopharmaceutical industry in Asia and, in particular, South Korea, has entered a new phase characterized by a high innovation and investment pace on the part of our customers. With our significant investments in Songdo, we will be increasing capacities, moving production operations closer to our customers in the region and substantially accelerating our delivery speed,” said Joachim Kreuzburg, executive board chairman and CEO, Sartorius, in a company press release.